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Abacavir Pharmacogenetics – From Initial Reports to
Standard of Care
Michael A. Martin and Deanna L. Kroetz*
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California
Abacavir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of human
immunodeficiency virus infection as part of a multidrug, highly active antiretroviral therapy regimen.
Despite its efficacy, approximately 5% of individuals who receive abacavir develop an immune-medi-
ated hypersensitivity reaction (HSR) that warrants immediate discontinuation of abacavir and switching
to an alternative antiretroviral regimen. Abacavir HSR is associated with individuals who carry the
*57:01 variant in the human leukocyte antigen B (HLA-B) gene. There is a large volume of evidence to
show that those who carry HLA-B*57:01 are at significantly increased risk of developing HSR and
should not receive abacavir. Pharmacogenetic screening to ensure individuals who carry HLA-B*57:01
do not receive abacavir can reduce the incidence of HSR and is now considered the standard of care
before prescribing abacavir. Genetic testing to prevent abacavir HSR is currently one of the best exam-
ples of integrating pharmacogenetic testing into clinical practice.
KEY WORDS abacavir, HIV, AIDS, genetic testing, HLA, drug hypersensitivity, pharmacogenetics.
(Pharmacotherapy 2013;33(7):765–775) doi: 10.1002/phar.1278
Abacavir is a nucleoside analogue reverse
transcriptase inhibitor (NRTI) first released in
1998 by GlaxoSmithKline for the treatment of
human immunodeficiency virus (HIV) infection.
It is available as a single agent (Ziagen; also
available in generic formulations in the United
States) as well as in the combination NRTI drugs
(Epzicom/Kivexa [with lamivudine] and Trizivir
[with lamivudine and zidovudine], ViiV Health-
care, Brentford, United Kingdom). Although
abacavir is safe and effective for the treatment of
HIV, approximately 5% of the population1 is at
risk of developing potentially life-threatening
hypersensitivity reactions (HSR) to abacavir ther-
apy.2 Although the presentation of symptoms
predicted that abacavir HSR was immune-
mediated, it took several years after its wide-
spread use to discover genetic predictors of
abacavir HSR. A variant allele in the HLA-B
gene, a critical part of the immune system, was
shown to strongly correlate with the risk of
developing abacavir HSR.3 After the publication
of these findings, clinicians began to screen
patients with HIV for the presence of HLA-
B*57:01 and selectively prescribe abacavir only
to those that did not carry the allele. A number
of clinical studies, most notably the landmark
PREDICT-14 study, showed that pharmacogenetic
testing for HLA-B*57:01 resulted in a significantly
decreased incidence of abacavir HSR. Based
on these findings, screening for HLA-B*57:01 is
now considered routine clinical practice before
prescribing abacavir. This review will summarize
general background on abacavir and HLA-
B*57:01, the clinical studies linking HLA-B geno-
type to abacavir HSR risk, the integration of
pharmacogenetic testing into clinical practice,
and the impact genetic testing has had on abaca-
vir HSR risk.
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Signs and Symptoms of Abacavir
Hypersensitivity
Per the black box warning on abacavir-
containing products,5 HSR is defined as a sign
or symptom in two or more symptom groups
(Table 1). These signs and symptoms are nor-
mally mild at onset, but will continue to
increase in severity with continued abacavir
exposure. True HSR occurs within the first days
or weeks of abacavir exposure, with the median
time to onset of symptoms around 11 days.1
Symptoms of HSR that occur many months or
years into abacavir exposure are unlikely to be
true HSR and are more likely explained by infec-
tion or an adverse drug response to another
drug. If HSR is suspected or cannot be ruled
out, abacavir should be immediately withdrawn,
an allergy to abacavir should be noted in the
patient’s chart, and the patient should be
switched to an alternative antiretroviral. Cessa-
tion of symptoms shortly after abacavir with-
drawal should also provide confidence in the
diagnosis of HSR. Abacavir rechallenge is
contraindicated in a patient with suspected HSR
due to the potential for severe and life-threaten-
ing reactions.2, 6
Abacavir skin patch testing (SPT) has been
performed in many research studies to confirm a
clinical diagnosis of HSR. The method of testing
is essentially the same as a standard SPT for
allergens. Abacavir solution, typically in the
range of 1–10% in a petrolatum base, is applied
to a patch placed on a patient’s skin, usually on
the back.7 Between 24 and 48 hours later, the
test results are then “read” by looking for an
immune response at the sites of abacavir expo-
sure, including redness, induration, itchiness,
and blistering. The landmark PREDICT-1 study4
used abacavir SPT results to distinguish “immu-
nologically-confirmed” HSR from clinically-diag-
nosed HSR. Although PREDICT-1 and other
studies8, 9 have shown exceptional correlation
between positive SPT results and the presence of
HLA-B*57:01, it is unclear what the false-nega-
tive rate for this test truly is. In addition, clini-
cian error in applying the test or other patient
factors, such as concomitant illnesses or drugs,
may contribute to false-negative results. Because
rechallenge with abacavir is contraindicated in
individuals with clinically suspected HSR, it is
unlikely that the accuracy of this test will ever
be fully determined. As such, SPT is part of the
research setting, but is not recommended for use
in clinical practice to confirm hypersensitivity.
Abacavir Mechanism of Action
Like many other NRTIs, abacavir is a prodrug
that requires intracellular phosphorylation10 to
produce its active metabolite, carbovir triphos-
phate11 (Figure 1). Carbovir triphosphate is able
to inhibit viral reverse transcriptase by compet-
ing with endogenous deoxyguanosine triphos-
phate at the active site. On incorporation into
the newly synthesized viral DNA, carbovir tri-
phosphate is able to induce chain termination
due to its lack of the 3′ hydroxyl group neces-
sary to form the critical phosphodiester bonds in
the backbone of DNA, effectively halting the
reverse transcription process.
Abacavir Metabolism and Elimination
Unlike protease inhibitors and nonnucleoside
reverse transcriptase inhibitors, abacavir is not a
significant substrate, inhibitor, or inducer of any
members of the cytochrome P450 family. This
makes it an attractive choice for patients receiving
other cytochrome P450 substrates to avoid poten-
tial drug-drug interactions. Once absorbed, abaca-
vir is extensively metabolized, with less than 2%
of the oral dose being excreted into the urine as
parent drug.12 One pathway for metabolism of
abacavir is through UDP-glucuronosyltransferases
to produce the 5′-glucuronide (Figure 1).
Although there have been a number of studies of
the pharmacogenetics of glucuronidation of the
protease inhibitor atazanavir, similar studies have
not been done for abacavir. Therefore, it is
unclear at the present time which UDP-glucuron-
osyltransferase isoforms metabolize abacavir and
whether genetic variation in these genes affects
abacavir metabolism. Abacavir is also metabolized
by alcohol dehydrogenase to produce an aldehyde
intermediate that is then converted to a 5′-carbox-
ylate derivative. Previous data have shown that
ingestion of moderate amounts of ethanol can
increase the area under the curve and half-life of
a single 600-mg dose of abacavir,13 with a shifting
Table 1. Grouping of HSR Signs and Symptoms
Signs and Symptoms of Abacavir HSR
Group 1 Fever
Group 2 Rash
Group 3 (Gastrointestinal) Nausea, vomiting, diarrhea,
abdominal pain
Group 4 (Constitutional) Malaise, fatigue, achiness
Group 5 (Respiratory) Dyspnea, cough, pharyngitis
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of abacavir metabolism toward the glucuronida-
tion pathway.
Approximately 85% of a given oral dose of
abacavir is eliminated renally, with the majority
of it as a roughly equal mix of the carboxylate
and glucuronide metabolites and limited amounts
of other minor metabolites and unmetabolized
abacavir.12 The remainder of the dose is elimi-
nated fecally as a mixture of unmetabolized
abacavir and the carboxylate metabolite. In phar-
macokinetic studies performed in individuals
with renal impairment (creatinine clearance < 60
ml/min) or on hemodialysis who had received
abacavir for at least 2 months,14 there were no
observed changes in pharmacokinetic parameters.
This may make abacavir an attractive choice in
patients with impaired renal function.15
Function of HLA-B
The HLA-B gene is one of many genes con-
tained in the HLA locus on chromosome 6, the
human equivalent of the major histocompatibility
complex (MHC) found in virtually all verte-
brates. The HLA-B gene is a member of the MHC
class I genes, along with HLA-A and HLA-C. The
MHC class I genes encode proteins that hetero-
dimerize with b2 microglobulin to form a func-
tional complex that binds intracellular peptides
in the endoplasmic reticulum.16 After peptide
loading, these complexes traffic to the cell sur-
face and “present” the peptide to circulating T
cells. Normally, the peptides presented are the
normal degradation products of intracellular
proteins and do not produce a response in T
cells because they are recognized as “self.” How-
ever, sometimes the peptide presented is recog-
nized as “nonself,” either because it originated
from an intracellular pathogen, such as a virus
or bacteria, or because its amino acid sequence
is otherwise abnormal. This indicates that some-
thing has gone wrong inside the cell, such as
genetic mutations and dysregulation that might
lead to cancer. In such cases, the T cell will then
activate and proceed to destroy the cell.
Variation in HLA Genes
The ability of an HLA molecule to successfully
load and present a given peptide is directly
related to that molecule’s amino acid sequence,
particularly within the peptide binding groove.
Due to the diverse and ever-evolving genomes of
human pathogens, there is constant selective
pressure for the appearance of new HLA alleles
that better protect against infections caused by
these pathogens. In addition, because of codomi-
nant expression of HLA genes, it is evolution-
arily advantageous for a given individual to have
two different alleles of each HLA gene, effec-
tively providing a significantly larger peptide
binding repertoire than an individual who was
homozygous at all HLA alleles. These effects
have resulted in HLA genes that are some of the
most polymorphic in the entire human
genome,17 but have also resulted in considerable
Figure 1. Metabolism and activation of abacavir. Abacavir is rapidly absorbed after oral dosing and is quickly taken up into
cells by passive diffusion, where it is then phosphorylated by adenosine phosphotransferase to produce abacavir. A cytosolic
deaminase converts abacavir monophosphate to carbovir monophosphate, which is then subject to processing by other
intracellular kinases to produce the active metabolite, carbovir triphosphate.
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differences in HLA allele distribution among
populations.
Although the evolution of HLA alleles is dri-
ven in response to environmental exposure to
new pathogens and helps strengthen human
immunity, this process is not without its draw-
backs. The high variability in HLA alleles makes
it exceedingly difficult to find suitable donors
for organ and bone marrow transplants.18 HLA
mismatches between donor and recipient cur-
rently require lifelong use of immunosuppres-
sants to prevent acute rejection of the organ,
ultimately placing the recipient at increased risk
of infection and cancer. Other than identical
twins, it is highly unlikely to find a suitable
organ donor that is a perfect match across all
HLA loci.
Certain HLA alleles have also been associated
with an increased risk of developing a number
of autoimmune conditions, such as ankylosing
spondilitis19 and rheumatoid arthritis.20 Despite
decades of research, it is still unclear how these
alleles contribute to an increased risk of autoim-
mune disease. It is also unclear how alleles that
predispose individuals to these debilitating con-
ditions could reach reasonable frequencies in the
population. It may be that at one time they pro-
vided an advantage against a particular patho-
gen, leaving behind the risk of autoimmunity as
an unfortunate side effect.
Particular HLA alleles are also associated with
an increased risk of rare, serious drug toxicities,
including Stevens-Johnson syndrome and toxic
epidermal necrolysis, collectively referred to as
severe cutaneous adverse reactions.21 Associa-
tions have been shown with HLA-B*15:02 and
risk of carbamazepine-induced Stevens-Johnson
syndrome in East Asian populations,22 as well as
HLA-B*58:01 for allopurinol-induced severe
cutaneous adverse reactions in European popula-
tions.21 In addition to abacavir hypersensitivity,
HLA-B*57:01 has also been associated with flucl-
oxacillin-induced hepatotoxicity,23 although the
absolute risk is substantially less than abacavir
hypersensitivity. Furthermore, although these
HLA alleles are associated with increased risk
for adverse events, they are by no means a guar-
antee that a reaction will occur, suggesting that
other genetic and environmental factors also
play a role in the development of these acute
drug toxicities. In the case of flucloxacillin, only
1 in 500–1000 drug-exposed patients carrying
HLA-B*57:01 will actually develop hepatotoxic-
ity.23
HLA-B*57:01 Allele Frequency in Worldwide
Populations
The presence of HLA-B*57:01 can be detected
in many populations worldwide and is highly
variable. Table 2 summarizes the allele fre-
quency ranges for many ethnic groups. Cauca-
sian populations generally possess HLA-B*57:01
in the range of 6–10%. African populations,
however, have only a 1–2% carrier rate and, as
expected, have a lower incidence of abacavir
HSR. East Asian populations typically have a
1–3% carrier rate, though some populations
have shown higher allele frequencies.25, 26 How-
ever, HLA-B*57:01 is only present at a very low
rate in Korean populations27 and is virtually
absent in Japanese populations.28 Strikingly,
many Indian populations have very high HLA-
B*57:01 allele frequency, with some in excess of
a 15% carrier rate.29
Potential Mechanisms of Abacavir
Hypersensitivity
A number of different mechanisms have been
proposed for mediating abacavir HSR. One pro-
posed mechanism hypothesizes that abacavir
itself may covalently bind to a peptide that is a
normal ligand for HLA-B*57:01, effectively mak-
ing abacavir a hapten against which the immune
system begins to mount a defense.30 Abacavir’s
metabolism by alcohol dehydrogenase produces
an aldehyde intermediate that then goes on
to become abacavir carboxylate (Figure 1).
Reactive aldehydes produced from endogenous
compounds, such as the byproducts of lipid per-
oxidation, can form adducts with cellular pro-
teins, producing cellular damage hypothesized to
contribute to a wide variety of phenotypes,
including neurodegeneration31 and cardiovascu-
lar disease.32
Table 2. Allele Frequency of HLA-B*57:01 in Various Pop-
ulation Groups24
Population Group
HLA-B*57:01 Carrier
Frequency Range (%)
European 1.4–10.2
South American 1.1–3.1
African 0.0–3.2
Middle Eastern 0.5–6.0
Mexican 0.0–4.0
Asian 0.0–6.7
Southwest Asian (Indian) 3.8–19.6
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Abacavir’s aldehyde metabolite forms adducts
to the valine residues of cellular proteins,33
lending some credibility to the hypothesis that
one or more haptenated peptides may be the
mediator of abacavir HSR. Although this may
occur in vivo, it remains unclear whether there
are specific proteins with which abacavir will
adduct, allowing for a potential connection
between these proteins and the peptide binding
repertoire of HLA-B*57:01 versus other alleles.
Another proposed mechanism suggests that
abacavir or one of its metabolites may interact
with the HLA-B*57:01 protein, possibly in or
near the peptide binding groove, to alter its
binding repertoire. With its repertoire altered,
HLA-B*57:01 would then begin to present novel
self-peptides to immune cells, leading to the
immune response. Recently published data show
that abacavir treatment can indeed alter the pep-
tide binding repertoire of a soluble form of HLA-
B*57:01 expressed in a lymphoblastoid cell
line.34 Although abacavir treatment resulted in
loading of novel self-peptides, the C-terminal
amino acids of these peptides were not consis-
tent with peptides that are normally loaded onto
HLA-B*57:01 in the absence of abacavir; how-
ever, when these peptides were synthesized and
tested for binding to purified HLA-B*57:01 pro-
tein, it was found that these peptides bind even
in the absence of abacavir and that addition of
abacavir had no detectable effect on the binding
affinity. This suggests that even though these
peptides can bind to isolated and purified HLA-
B*57:01, they are prevented from doing so under
normal intracellular conditions. Of note, fluclox-
acillin treatment had no effect on the binding
repertoire of HLA-B*57:01 in this experimental
system. Given that some of the novel self-pep-
tides loaded onto HLA-B*57:01 in the presence
of abacavir are from proteins expressed in the
liver and might provide a possible link to the
increase in hepatotoxicity risk of flucloxacillin,
it would appear that abacavir and flucloxacillin
may interact with HLA-B*57:01 through distinct
mechanisms.
Another recent report35 also shows that abaca-
vir can modify the peptides presented by HLA-
B*57:01. Although the peptides used in this
experimental system come from peptide libraries,
the results show a clear shift in the C-terminal
residues of bound peptides after abacavir is
added. Under normal circumstances, HLA-
B*57:01 prefers large hydrophobic residues such
as tryptophan and phenylalanine in the C-termi-
nus of bound peptides, but this shifts to valine,
alanine, and isoleucine when cotreated with
abacavir. In addition, the group was able to suc-
cessfully crystallize HLA-B*57:01 in the presence
of a bound peptide and abacavir. As previously
hypothesized, abacavir binds directly in the pep-
tide binding groove of HLA-B*57:01 and disrupts
where the C terminus of endogenous peptide
ligands would typically bind (Figure 2). Metabo-
lites of abacavir were not tested, but may also
have some effect on peptide binding. However, it
is clear from the results of these experiments that
abacavir is able to bind to HLA-B*57:01 directly
and alter its peptide binding repertoire, lending
credibility to the hypothesis that novel self-
peptide presentation is responsible for or plays a
significant part in abacavir HSR.
Initial Studies Linking HLA-B*57:01 to
Abacavir HSR
The first retrospective study linking HLA-
B*57:01 to abacavir HSR risk was published in
early 2002 and involved the first 200 patients
exposed to abacavir in the Western Australian
HIV Cohort Study3 (Table 3). The patients, who
were primarily male and white, were HLA-typed
across multiple HLA genes, including HLA-A,
HLA-B, HLA-C, HLA-DR, and HLA-DQ. A single
clinician, who was blinded to each patient’s
HLA genotype, reviewed their medical records
to look for evidence of hypersensitivity per
established diagnostic criteria. These included at
least two HSR symptoms within the first
Figure 2. Binding of abacavir to HLA-B*57:01. Abacavir
(shown in red) binds within the F pocket of HLA-B*57:01
where the C-terminal residues of bound peptides would
normally bind, altering its binding repertoire. Presentation
of alternative peptides (shown in blue) to the immune
system is hypothesized to trigger abacavir HSR. This image
was rendered from PDB file 3UPR.
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6 weeks of abacavir exposure. Additional criteria
included resolution of symptoms within 72 hours
after abacavir withdrawal and the absence of a
likely alternative explanation for the patient’s
symptoms.
Among the cohort, 18 “definite” cases of
abacavir HSR were identified, all of whom were
white. As well, 167 abacavir-tolerant (control)
individuals and an additional 15 individuals who
experienced nonspecific symptoms were identi-
fied but did not meet the established criteria for
HSR diagnosis. HLA-B*57:01 was present in 14
(78%) of the “definite” abacavir HSR cases ver-
sus only 4 (2.4%) in the abacavir-tolerant con-
trols (odds ratio [OR] 117, 95% confidence
interval [CI] 29–481, p<0.0001). In addition,
the HLA-DR7 and HLA-DQ3 alleles were present
in HSR cases at a significantly higher level than
controls. Across the entire cohort, the haplotype
of HLA-B*57:01, HLA-DR7, and HLA-DQ3 was
found to have a positive predictive value (PPV)
of 100% and negative predictive value (NPV) of
97%. These investigators then began performing
genetic screening in all abacavir-eligible patients
and did not prescribe abacavir to individuals
who carry the HLA-B*57:01, HLA-DR7, HLA-
DQ3 haplotype. However, because their cohort
was mostly male and white, these findings
Table 3. Summary of Pharmacogenetic Studies and Their Key Findings With Regard to HLA-B*57:01 and Abacavir HSR
Year
Published Authors Study Type Key Findings
2002 Mallal et al.3 Retrospective HLA-B*57:01 is a significant predictor of abacavir HSR, present in 78% of
HSR cases, vs only 2.4% in the abacavir-tolerant controls in a population
of predominantly Caucasian men
A haplotype of HLA-B*57:01, HLA-DR7, and HLA-DQ3 has a PPV of 100%
and an NPV of 97% for HSR
In the study population, denying abacavir to those carrying the haplotype
should reduce the incidence of HSR from 9% to 2.5%
2002 Hetherington et al.36 Retrospective HLA-B*57:01 is present in 44% of HSR cases, all but one of whom is
Caucasian
Only 29% of HSR cases carry the previously identified HLA-B*57:01,
HLA-DR7 haplotype
2004 Hughes et al.37 Retrospective HLA*57:01 is a significant predictor of HSR in both Caucasian men and
women
For the first time, HLA-B*57:01 is also shown to be a significant predictor
of HSR in Hispanics
2004 Martin et al.30 Retrospective Updated diagnostic criteria, including results of SPT (when available) were
used to reclassify previously diagnosed HSR cases in this mostly
Caucasian cohort
Using the updated criteria, HLA-B*57:01 was present in 94.4% of HSR
cases, compared with only 1.7% of controls
Using the updated criteria, HLA-B*57:01 has a PPV of 78.9% and an NPV
of 99.4%
2006 Rauch et al.38 Prospective After prospective screening for presence of HLA-B*57:01, none of the
HLA-B*57:01-negative individuals who received abacavir developed HSR
Prospective screening significantly reduced the incidence of HSR,
compared with previous rates of HSR before implementing screening
2008 Mallal et al.4 Prospective In a randomized, double-blind trial in a cohort of 1956 individuals,
clinically-diagnosed HSR was significantly reduced in the
prospective-screening group vs control (3.4% vs 7.8%)
There were zero cases of immunologically-confirmed HSR in the
prospective-screening group, vs 2.7% in the control group
HLA-B*57:01 testing has a PPV of 47.9% and an NPV of 100%
Introduction of an NNRTI and concurrent PI use are significant predictors
of clinically diagnosed, but not immunologically-confirmed, HSR
2008 Saag et al.8 Retrospective 32.3% of white patients with clinically-diagnosed HSR had
immunologically-confirmed HSR, vs only 7.2% of clinically-diagnosed
HSR cases in blacks
Among both white and black patients, all individuals with
immunologically-confirmed HSR were HLA-B*57:01-positive
Although immunologically-confirmed HSR is rare in black individuals,
HLA-B*57:01 has 100% sensitivity for identifying cases
HSR = hypersensitivity reaction; PPV = positive predictive value; NPV = negative predictive value; SPT = skin patch testing; NNRTI = nonnu-
cleoside reverse transcriptase inhibitors; PI = protease inhibitor.
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required replication in women and other ethnici-
ties.
Only weeks after these findings were pub-
lished, GlaxoSmithKline released their own ret-
rospective case-control study36 replicating the
predictive value for HLA-B*57:01, but again
noted the need to replicate these findings in
women and other ethnic groups. In a multicen-
ter, retrospective follow-up study37 published in
2004, GlaxoSmithKline investigators replicated
their original findings in white men and
extended the predictive value of HLA-B*57:01 to
white women and Hispanics. The GlaxoSmithK-
line study showed no association between HLA-
B*57:01 and HSR in black patients, the majority
of whom were African American.37 Among the
cases, there were fewer black HLA-B*57:01 carri-
ers than whites or Hispanics, which may simply
be due to HLA-B*57:01 being less common in
blacks compared with the other ethnic groups
(Table 2). The low frequency of the risk allele
and the possible misclassification of abacavir
cases in this group could have limited the ability
to detect a significant association between geno-
type and HSR.
The Western Australian HIV Cohort Study
published their own follow-up study30 in 2004
consisting of a reanalysis of their original 200
patients3 and an additional 48 individuals who
enrolled after prospective screening for HLA-
B*57:01 was instituted. All patients were reclas-
sified as cases or controls based on updated
diagnostic criteria, which included the results of
SPT when available. The reclassification resulted
in 18 HSR cases and 230 abacavir-tolerant con-
trols. Again, HLA-B*57:01 was a significant pre-
dictor of abacavir HSR, being present in 17
(94.4%) of the cases and only 4 (1.7%) of the
controls.30 Being a carrier of HLA-B*57:01 was
associated with an OR of 960 of developing
HSR. Genotyping for the presence of HLA-
B*57:01 had a PPV of 78.9% and an NPV of
99.4% for predicting incidence of HSR, support-
ing a role for the clinical utility in Caucasian
populations.
In another follow-up study,38 the authors
from the Western Australia HIV Cohort Study
focused on patients entering the study since
2002, all of whom were prospectively screened
for HLA-B*57:01. The overall carrier rate of
HLA-B*57:01 in this population of 260 treat-
ment-na€ıve and treatment-experienced patients
was 7.7%. Skin patch testing was performed in
all cases of suspected HSR and in patients for
whom hypersensitivity could not be ruled out
and who consented to testing. Among 151 indi-
viduals given abacavir during the course of the
study, none of the 148 HLA-B*57:01-negative
patients experienced HSR. Despite screening,
three HLA-B*57:01-positive white patients
received abacavir and all three experienced HSR
confirmed by SPT. Two of these cases were due
to abacavir being mistakenly prescribed before
HLA typing results were reviewed. The third
case was due to the patient willingly starting ab-
acavir despite being a carrier of HLA-B*57:01.
This patient was not a carrier of the HLA-DR7
and HLA-DQ3 alleles previously linked to HSR,3
suggesting that carrying HLA-B*57:01 alone was
sufficient to develop HSR. The HSR rate in this
prospectively screened group of patients was
2.0%, representing a significant decrease from
the 8.0% incidence of abacavir HSR before
genetic screening.38
PREDICT-1
The results of PREDICT-1, the first random-
ized, double-blind, placebo-controlled trial for
the evaluation of a pharmacogenetic test to
reduce adverse events, were published in The
New England Journal of Medicine in early 2008.4
The study enrolled 1956 HIV-positive abacavir-
naive individuals in 19 countries who were
mostly white (84%) and male (72%). Participants
were divided between the “standard of care” con-
trol group, which received no HLA-B*57:01 test-
ing, and the prospective screening group, where
all individuals were genetically tested and only
HLA-B*57:01-negative individuals could be pre-
scribed abacavir. All patients with clinically-diag-
nosed HSR also had SPT performed within
6–10 weeks of the original reaction.
Overall, 3.4% of patients in the prospective
screening group and 7.8% of those in the control
group were clinically diagnosed with abacavir
HSR, showing a significant reduction in the pro-
spective screening group (OR 0.40, 95% CI
0.25–0.62, p<0.001). Furthermore, there were
no cases of immunologically-confirmed HSR in
the prospective screening group compared with
23 (2.7%) in the control group (OR 0.03,
95% CI 0.00–0.18, p<0.001). HLA-B*57:01 posi-
tivity had a sensitivity of 100% for predicting
immunologically-confirmed HSR, as well as a
specificity of 96.9%, PPV of 47.9%, and NPV of
100%. Despite the strength of these findings,
their applicability to the wider patient popula-
tion was limited because the PREDICT-1 cohort
was predominantly white and male.
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In a multivariate analysis of covariates that
might be associated with HSR, introduction of a
nonnucleoside reverse transcriptase inhibitor
and concomitant use of a protease inhibitor were
both associated with clinically-diagnosed HSR;
these were the only factors associated with clini-
cally-diagnosed but not immunologically-con-
firmed HSR. These results suggested that adverse
drug reactions to other antiretrovirals were pre-
sumably being attributed to abacavir HSR. This
highlights the need for clinical vigilance, as
HLA-B*57:01 is not predictive for reactions that
may present with similar symptoms.
SHAPE
Shortly after the publication of PREDICT-1,
the results of the retrospective SHAPE study
were published.8 The purpose of this study was
to evaluate the sensitivity and specificity of HLA-
B*57:01 as a marker for SPT-confirmed abacavir
HSR. In addition, because of the lack of data on
the predictive ability of HLA-B*57:01 in black
individuals, the SHAPE study was specifically
designed to validate HLA-B*57:01 screening in
black and white cohorts that would be evaluated
separately. A total of 130 white patients and 69
black patients, identified by a previous clinical
diagnosis of HSR, underwent SPT. Between the
two groups, 32.3% of the white patients and
7.2% of the black patients had a positive SPT
and all were HLA-B*57:01 positive. In both
white and black patients, presence of HLA-
B*57:01 had a sensitivity of 100% for predicting
immunologically-confirmed HSR. Specificity was
also very high in both populations – 96% in
white patients and 99% in black patients. This
clinical trial validated the use of HLA-B*57:01
testing in blacks, although immunologi-
cally-confirmed HSR is rare in this patient popu-
lation overall.
Incorporation into Clinical Practice
Though the results of PREDICT-1 and SHAPE
were formally published in early 2008, the find-
ings had already been presented in the summer
of 2007 at the International AIDS Society Con-
ference. LabCorp, a U.S.–based national refer-
ence laboratory, had been offering HLA-B*57:01
testing since early 2005 in response to the initial
clinical studies and physician requests. Test vol-
ume was low, came from only a small number
of physicians, and remained that way for several
years. However, once the results of PREDICT-1
and SHAPE were presented, test volume
increased 5-fold over a 6-month period.39
In late 2007, the recommendation for HLA-
B*57:01 screening was added to the Department
of Health and Human Services HIV Guidelines40
and test utilization continued to increase. In July
2008, the U. S. Food and Drug Administration
(FDA) issued an advisory to clinicians and
updated the package inserts for all products con-
taining abacavir, warning of the risk of HSR in
HLA-B*57:01-positive individuals. The labeling
change recommended screening all patients for
HLA-B*57:01 before starting abacavir therapy,
regardless of a patient’s ethnicity. The label
change also recommended screening all individ-
uals of unknown HLA-B*57:01 status before
reinitiation of abacavir, even if they had previ-
ously tolerated it without incident. In addition,
the FDA recommended that abacavir be immedi-
ately discontinued if HSR could not be ruled
out, even when other diagnoses were possible.
However, the momentum for increased testing
had already been generated, making the FDA
updates more of a confirmation of what clini-
cians were already practicing rather than a new
recommendation.
Since that time, a number of HIV and pharma-
cogenetic guidelines have recommended the use
of HLA-B*57:01 testing in all abacavir-na€ıve indi-
viduals,24, 41–44 firmly establishing it as the stan-
dard of care before prescribing abacavir. More
recent HIV clinical trials have demonstrated a
decreased incidence of abacavir HSR after integra-
tion of baseline genetic screening. In the Euro-
pean ASSERT study,45 all individuals were
screened to confirm they were HLA-B*57:01-neg-
ative before being randomized to the abacavir-
lamivudine or tenofovir-emtricitabine arms. In
the abacavir treatment arm, only six individuals
(3%) reported experiencing abacavir HSR, a sig-
nificant decrease from historical averages before
genetic screening.1, 3 In the multicenter ARIES
study,46 only 4 of 515 HLA-B*57:01-negative
patients had clinically suspected HSR. Moreover,
when these patients later underwent SPT, all four
results were negative.
Methods of Testing for HLA-B*57:01
There are many different ways to test for
HLA-B*57:01. One such method is direct
sequence-based typing, which amplifies the
entire genomic region of HLA-B from both chro-
mosomes using polymerase chain reaction
(PCR). After amplification, the DNA fragments
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are then directly sequenced and checked against
known HLA-B alleles. The results from the test
are reported as the diplotype of both HLA-B
alleles present (e.g., HLA-B*57:01 and HLA-
B*07:02). Direct sequencing is considered the
gold standard for HLA alleles, but it is also the
most expensive, time consuming, and resource
intensive. Because HLA-B*5701 is the only allele
of interest in abacavir HSR, direct sequencing is
not generally performed.
One common method of testing for HLA-
B*57:01 uses allele-specific PCR.47 In this
method, oligonucleotide probes are specifically
designed for HLA-B*57:01 and will not amplify
any other HLA-B alleles.48 Results are reported
as either “positive” (i.., the patient is a carrier of
HLA-B*57:01) or “negative” (i.e. the patient does
not carry HLA-B*57:01), making them easy to
interpret. The results of samples assayed using
allele-specific PCR maintain near perfect concor-
dance with the results of sequence-based typ-
ing49 and are consistent across different testing
sites.
Some labs also test for HLA-B*57:01 by assay-
ing for a single nucleotide polymorphism (SNP)
near the HLA-B gene. This SNP (rs2395029) is
located in the HLA complex P5 gene approxi-
mately 100 kilobases away from HLA-B. Testing
for the presence of this SNP is less time and
resource intensive than other methods, making
it an attractive option for many labs. There is a
strong linkage disequilibrium between
rs2395029 and HLA-B*57:01, meaning that these
variants are typically coinherited, in some Cau-
casian50, 51 and Hispanic52 populations. There-
fore, testing for the presence of rs2395029 could
be used as a surrogate marker for the presence
of HLA-B*57:01. Although complete linkage dis-
equilibrium has been observed in some popula-
tions, many others do not have complete linkage
disequilibrium between HLA-B*57:01 and
rs2395029.53 When these variants are not inher-
ited together, testing for rs2395029 could lead
to an incorrect assumption about whether a
patient carries HLA-B*57:01. This ultimately
leads to decreased sensitivity and specificity and
increased false-positive and false-negative rates
for this test when compared with approaches
that directly assess whether HLA-B*57:01 is pres-
ent. Although denying abacavir to someone that
is truly HLA-B*57:01 negative is unlikely to be
of serious clinical consequence, improperly pre-
scribing abacavir to someone that carries HLA-
B*57:01 places this patient at significant risk for
HSR. In addition, the linkage between
rs2395029 and HLA-B*57:01 is not well studied
in African and Asian populations, making this
assay of questionable use in these groups.
Despite these potential problems, some reference
labs continue to use this test as a marker for
HLA-B*57:01. Clinicians should be keenly aware
of what methods are being used when they order
HLA-B*57:01 testing and keep this in mind
when examining cases of suspected HSR.
Conclusions
The story of abacavir HSR highlights a critical
component of successful pharmacogenomic stud-
ies: a clearly defined phenotype. Because of the
generalized nature of most HSR symptoms, the
clinical presentation of HSR can be mistaken for
the acute onset of a viral or bacterial infection or
an adverse reaction to other drugs. Before imple-
mentation of genetic screening, the clinical diag-
nosis of HSR likely included true cases of
abacavir HSR along with a significant number of
illnesses that manifested as similar symptoms.4
Because rechallenge with abacavir is contraindi-
cated, it was essentially impossible at the time to
separate true abacavir HSR from a false-positive
diagnosis. This has also resulted in significant
differences in clinical diagnosis rates between
studies,1, 3 making comparisons between them
difficult. After SPT began to identify true cases of
HSR in a more agnostic manner, it was clear that
many people clinically diagnosed with abacavir
HSR were not, in fact, true cases.30 Not surpris-
ingly, when cases and controls were reassigned
based on positive SPT results, HLA-B*57:01
became an even stronger predictor of HSR.30
The evolution of abacavir and HLA-B*57:01
from initial finding to standard of care may also
serve as a useful guide for clinical implementa-
tion of other pharmacogenomic tests. Abacavir is
a rarity in the world of pharmacogenomics
because of our ability to successfully integrate
genetic screening into normal clinical practice in
just a matter of years. One of the longstanding
challenges in pharmacogenomics has been the
difficulty in translating all of the novel findings
into guided clinical actions. Many pharmacoge-
netic tests have been clinically available for
years, but are underused by clinicians.54
What has really been so special about abaca-
vir? Part of its success may be that clinicians
focusing on HIV treatment are a relatively small
group. As such, it is comparatively easy to reach
a significant portion of them at a scientific
conference or with the latest journal article.
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This may have allowed information on abacavir
pharmacogenetics to travel through the HIV
community at a much quicker pace than phar-
macogenetics would have been disseminated
through much larger fields such as cardiovascu-
lar disease or diabetes. In addition, HIV clini-
cians were already used to and familiar with
genetic tests through interpreting viral resistance
panels, so the barriers to adding another genetic
test may have been lower than in other fields.
Although viral resistance panels deal directly
with the genetics of the HIV virus and HLA-
B*57:01 is a component of the entirely separate
host genetics, the basic principle that specific
genotypes guide particular therapeutic choices is
the same. It may be possible to ease this barrier
to implementation with the routine introduction
of pharmacogenomics into medical and phar-
macy school curricula. As well, the increasing
number of drugs under development for individ-
uals with a particular genotype will hopefully
increase clinician understanding and apprecia-
tion for how genetics can influence and enhance
therapeutic decisions.
Abacavir likely also benefited from the quick
appearance of HSR, and which presented as a
phenotype that was relatively easy to follow and
manage. Many pharmacogenetic associations
deal directly with drug pharmacokinetics or
pharmacodynamics, requiring an extra stage of
experimentation to determine what the optimal
increased or decreased dosing of these drugs
should be to match a particular genotype.55, 56
If the gene in question has a significant number
of isoforms or SNPs, this only adds to the com-
plexity and difficulty. Dosing information is crit-
ical in the design of prospective clinical trials;
unfortunately these trials could involve years of
follow-up if the drug is used to prevent long-
term outcomes and may require trial and error
before optimal dosing is found. Abacavir is unu-
sual in the speed at which genetic testing was
implemented, perhaps because, a significant
number of steps could be ignored that other
pharmacogenetic tests have to address.
Consequently, it might be that abacavir and
HLA-B*57:01 genotyping success lies in its sim-
plicity. There was no complicated dosing to
work out and the clinical trials did not require
years of follow-up. The only choice available to
clinicians regarding abacravir was to use the
drug or not use the drug.1, 2 Although there is
no doubt that the field of pharmacogenomics
must push ahead to answer the tough questions,
perhaps we should focus more on toxicities that
can help us make decisions about whether to
use a particular drug. Maybe then we can dupli-
cate the lessons learned from abacavir and gen-
erate the next pharmacogenetic success story.
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